Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Zendy

Brian I. Rini | Zendy; Elizabeth R. Plimack | Zendy; V.P. Stus | Zendy; Rustem Gafanov | Zendy; Robert D. Hawkins | Zendy; Dmitry Nosov | Zendy; Frédéric Pouliot | Zendy; B. Yа. Alekseev | Zendy; Denis Soulières | Zendy; Bohuslav Melichar | Zendy; Ihor Vynnychenko | Zendy; Anna Kryzhanivska | Zendy; Igor Bondarenko | Zendy; Sérgio Jobim Azevedo | Zendy; Delphine Borchiellini | Zendy; Cezary Szczylik | Zendy; Maurice Markus | Zendy; Ray McDermott | Zendy; Jens Bedke | Zendy; Sophie Tartas | Zendy; YenHwa Chang | Zendy; Satoshi Tamada | Zendy; Qiong Shou | Zendy; Rodolfo F. Perini | Zendy; Chen Mei | Zendy; Michael B. Atkins | Zendy; Thomas Powles | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Author(s) -

Brian I. Rini,

Elizabeth R. Plimack,

V.P. Stus,

Rustem Gafanov,

Robert D. Hawkins,

Dmitry Nosov,

Frédéric Pouliot,

B. Yа. Alekseev,

Denis Soulières,

Bohuslav Melichar,

Ihor Vynnychenko,

Anna Kryzhanivska,

Igor Bondarenko,

Sérgio Jobim Azevedo,

Delphine Borchiellini,

Cezary Szczylik,

Maurice Markus,

Ray McDermott,

Jens Bedke,

Sophie Tartas,

YenHwa Chang,

Satoshi Tamada,

Qiong Shou,

Rodolfo F. Perini,

Chen Mei,

Michael B. Atkins,

Thomas Powles

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1816714

Subject(s) - axitinib , sunitinib , pembrolizumab , renal cell carcinoma , medicine , oncology , urology , cancer , immunotherapy

The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research